Original Research

Time-intensity Curve Analysis of Hepatocellular Carcinoma using Two Contrast-enhanced Ultrasound Methods: Contrast Pulse Sequencing and Contrast Harmonic Imaging

  • He, MD, PhD Mengna ,
  • Xu, MD Lei ,
  • Jiang, MD, PhD Tian’an
Expand
  • a Department of Ultrasound, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
    b Department of Ultrasound, Jinhua Hospital of Zhejiang University, Jinhua, Zhejiang, China

Received date: 2020-02-12

  Online published: 2020-08-21

Abstract

Objectives: To compare the features of the time-intensity curve (TIC) of hepatocellular carcinoma (HCC) by two different contrast-enhanced ultrasound (CEUS) methods: Contrast Pulse Sequencing (CPS) and Contrast Harmonic Imaging (CHI).
Methods: This prospective study included 22 HCC lesions. The CPS and CHI (Cadence? technique by Siemens) were performed in random order for each lesion, and the microbubbles were completely cleared between the two methods. The imaging by each method was recorded for 10 minutes. The CEUS video clips were analyzed off-line and the quantitative parameters of time intensity curve were obtained: the peak intensity (PI), time to peak (TTP), washout time (WT), relative value (RV) of intensity and AUC before WT and after WT, and the time of RV ≥15 dB lasted (RLT).
Results: Compared with CPS, CHI showed an earlier WT (64.0 ± 17.1 s vs 33.1 ± 7.0 s) of HCC lesions, a lower RV of intensity (36.8 ± 9.4 vs 10.3 ± 5.1) and AUC (1377.2 ± 205.7 vs 227.2 ± 56.7) before WT, but higher RV of intensity (17.8 ± 4.6 vs 32.2 ± 8.6) and AUC (1 124.1 ± 276.4 vs 2 664.1 ± 456.8) after WT, and longer RLT (121.4 ± 49.8 s vs > 150 s).
Conclusion: For long later phase observation after washout, CHI is better than CPS, but the observation of rapid perfusion before washout is not comparable to CPS. A combined use of these two methods is recommended based on our research.

Cite this article

He, MD, PhD Mengna , Xu, MD Lei , Jiang, MD, PhD Tian’an . Time-intensity Curve Analysis of Hepatocellular Carcinoma using Two Contrast-enhanced Ultrasound Methods: Contrast Pulse Sequencing and Contrast Harmonic Imaging[J]. ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY, 2020 , 4(3) : 217 -222 . DOI: 10.37015/AUDT.2020.200007

References

[1] El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27.
[2] Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3:1683-91.
[3] Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67:358-80.
[4] Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015; 149: 1226 - 39. e4.
[5] Tao SM, Wichmann JL, Schoepf UJ, Fuller SR, Lu GM, Zhang LJ. Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention. Eur Radiol 2016; 26:3310-8.
[6] Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019; 38:200-14.
[7] Josep M Llovet, Michel Ducreux, Riccardo Lencioni, Adrian M Di Bisceglie, Peter R Galle, Jean Francois Dufour, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.Eur J Cancer 2012; 48:599-641.
[8] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.
[9] Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29:339-64.
[10] Kudo M. Defect Reperfusion Imaging with Sonazoid ?: A Breakthrough in Hepatocellular Carcinoma. Liver Cancer 2016 ; 5:1-7.
Outlines

/